Wolfe, Alnylam Pharmaceuticals
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from ...
Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...
Fintel on MSN1d
Wolfe Research Upgrades Warner Bros. Discovery (WBD)Fintel reports that on November 11, 2024, Wolfe Research upgraded their outlook for Warner Bros. Discovery (NasdaqGS:WBD) ...
Wolfe Research downgraded Altair to Peer Perform from Outperform. The firm notes on Wednesday, Altair (ALTR) announced that it has reached an agreement to be acquired by Siemens (SIEGY), for $113 ...
The upgrade is based on the firm's improving growth, more reasonable valuations, and its ability to deploy capital.
Wolfe Research has started-off Multi-family Residential REIT Elme Communities (NYSE:ELME) with a Peer Perform rating. In line with peer estimates in the apartment space, the company expects low ...
Wolfe Research initiated coverage of StandardAero (SARO) with an Outperform rating and $34 price target The firm says disruption in all areas of the plane manufacturer landscape make it a very ...
agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the 2024 Wolfe Research Healthcare ...
announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback